endpts.com·Jun 11, 2026
Neion Bio has raised $23 million in an oversubscribed Series A funding round to advance its technology that utilizes chicken eggs for producing active pharmaceutical ingredients.
Neion Bio's successful $23 million Series A funding round to develop technology for producing active pharmaceutical ingredients from chicken eggs highlights a significant investment opportunity in biotech innovation. This approach leverages a unique method of protein production, which could offer scalable and cost-effective alternatives in pharmaceutical manufacturing. This development is particularly relevant for those tracking advancements in biotech manufacturing and investment opportunities in novel biotechnologies.